相关实验视频

Updated: Jul 20, 2026

A Non-invasive Way to Isolate and Phenotype Cells from the Conjunctiva

A Non-invasive Way to Isolate and Phenotype Cells from the Conjunctiva

Published on: July 5, 2017

开发一种温度和pH值双重敏感的现场凝,用于治疗过敏结膜炎

Yanpeng Zhu¹, Yinghui Liu¹, Yongyue Wang¹

¹Department of Pharmaceutics, School of Pharmacy, Shenyang Pharmaceutical University, No. 103, Wenhua Road, Shenyang, 110016, P. R. China.

AAPS PharmSciTech

|September 25, 2024

概括

这项研究开发了一种针对过敏结膜炎的新型双重敏感的 in situ 凝,改善了 olopatadine 化的输送. 这种新配方证明了长时间的眼膜保留和减少炎症标志物,为过敏结膜炎提供了有前途的治疗方法.

科学领域:

眼科医生眼科眼科
药品制造药品制造药品制造
生物材料科学生物材料科学

背景情况:

过敏性结膜炎 (AC) 影响全球数百万人,需要改进治疗策略.
目前对AC的治疗方法经常面临有效性和眼部保留方面的挑战.
奥洛帕塔丁化是AC的关键治疗剂,但其输送可以优化.

研究的目的:

为了增强olopatadine化治疗过敏结膜炎的疗效.
开发一种新型的,无抗微生物的,对温度和pH双重敏感的in situ凝配方.
通过响应表面方法来优化配方,并确保有效的热杀菌.

主要方法:

开发一种温度-pH双重敏感的 in situ 凝,其中包含了 olopatadine 化物.
碳合物类型和度的评估和优化.
响应表面方法 (CCD-RSM) 中央复合材料设计,以优化波洛克萨默度.
最终配方 (TP凝) 在121°C进行热杀菌20分钟.

主要成果:

优化的双重敏感 in situ 凝 (TP-凝) 含有 0.1% 的 olopatadine 化物,18.80% 的 P407,0.40% 的 P188,0.30% 的 TR-1,4.0% 的曼尼托尔和0.08% 的 Tris.
TP凝表现出良好的安全性和长时间的眼睛表面保留 (大约2个月). 65.83分钟),比传统的眼液要长得多.
在过敏结膜炎的小鼠模型中,使用TP凝治疗显著降低了关键炎症标志物 (IL-13,IL-17,OVA-IgE).

结论:

开发的TP凝配方提供了一个有前途的,持续的输送系统为olopatadine化.
这种新的方法有效地减少了与过敏结膜炎相关的眼睛炎症.
温度-pH双敏感的现场凝技术为改进交流处理提供了可行的替代方案.

关键词:

在位凝在位凝过敏性结膜炎是一种过敏性结膜炎.这是一个双重敏感的敏感度.奥洛帕塔丁化

更多相关视频

Application of Biochip Microfluidic Technology to Detect Serum Allergen-specific Immunoglobulin E sIgE

Application of Biochip Microfluidic Technology to Detect Serum Allergen-specific Immunoglobulin E sIgE

Published on: April 21, 2019

Induction of Ocular Surface Inflammation and Collection of Involved Tissues

Induction of Ocular Surface Inflammation and Collection of Involved Tissues

Published on: August 4, 2022

相关概念视频

Open Angle Glaucoma: Treatment

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...

Ophthalmic Drug Delivery Systems

Ophthalmic Drug Delivery Systems

Ophthalmic drug delivery faces major limitations due to poor absorption across the corneal membrane. This process is primarily driven by diffusion and is influenced by two main factors: the physicochemical properties of the drug and tear drainage. Most ophthalmic drugs, such as pilocarpine, epinephrine, atropine, and local anesthetics, are weak bases. They are typically formulated at an acidic pH to enhance chemical stability. However, this leads to high ionization, reducing their ability to...